JP2006523694A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006523694A5 JP2006523694A5 JP2006509747A JP2006509747A JP2006523694A5 JP 2006523694 A5 JP2006523694 A5 JP 2006523694A5 JP 2006509747 A JP2006509747 A JP 2006509747A JP 2006509747 A JP2006509747 A JP 2006509747A JP 2006523694 A5 JP2006523694 A5 JP 2006523694A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- ethyl
- disorder
- dioxo
- carbon atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003118 aryl group Chemical group 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 18
- 125000004432 carbon atom Chemical group C* 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 125000001072 heteroaryl group Chemical group 0.000 claims 12
- 241000124008 Mammalia Species 0.000 claims 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims 10
- 208000002193 Pain Diseases 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 230000036407 pain Effects 0.000 claims 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 7
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 7
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 150000002148 esters Chemical class 0.000 claims 6
- 208000019901 Anxiety disease Diseases 0.000 claims 5
- 239000005711 Benzoic acid Substances 0.000 claims 5
- 235000010233 benzoic acid Nutrition 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 239000003937 drug carrier Substances 0.000 claims 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 206010010904 Convulsion Diseases 0.000 claims 4
- 208000001640 Fibromyalgia Diseases 0.000 claims 4
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 4
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 206010008118 cerebral infarction Diseases 0.000 claims 4
- 230000001684 chronic effect Effects 0.000 claims 4
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- 201000000980 schizophrenia Diseases 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- QDTOKEYAZZSRBV-UHFFFAOYSA-N 1-[1-benzoyloxyethoxy-[2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-6-yl)ethyl]phosphoryl]oxyethyl benzoate Chemical compound C1CCNC(C(C2=O)=O)=C2N1CCP(=O)(OC(C)OC(=O)C=1C=CC=CC=1)OC(C)OC(=O)C1=CC=CC=C1 QDTOKEYAZZSRBV-UHFFFAOYSA-N 0.000 claims 3
- 208000019022 Mood disease Diseases 0.000 claims 3
- 208000026106 cerebrovascular disease Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- -1 Benzoic acid [2- (8,9-dioxo-2,6-diaza-bicyclo [5.2.0] non-1 (7) -en-2-yl) -ethyl] -hydroxy-phosphinoyl Oxymethyl ester Chemical class 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 2
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000027534 Emotional disease Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 208000007514 Herpes zoster Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 206010026749 Mania Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- BDABGOLMYNHHTR-UHFFFAOYSA-N Perzinfotel Chemical compound OP(O)(=O)CCN1CCCNC2=C1C(=O)C2=O BDABGOLMYNHHTR-UHFFFAOYSA-N 0.000 claims 2
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000004450 alkenylene group Chemical group 0.000 claims 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 230000036592 analgesia Effects 0.000 claims 2
- 125000003435 aroyl group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 125000002837 carbocyclic group Chemical group 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 claims 2
- 239000003638 chemical reducing agent Substances 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 230000036461 convulsion Effects 0.000 claims 2
- VZFUCHSFHOYXIS-UHFFFAOYSA-N cycloheptane carboxylic acid Natural products OC(=O)C1CCCCCC1 VZFUCHSFHOYXIS-UHFFFAOYSA-N 0.000 claims 2
- 230000003412 degenerative effect Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 208000001286 intracranial vasospasm Diseases 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 230000036651 mood Effects 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 230000003533 narcotic effect Effects 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000000698 schizophrenic effect Effects 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 125000003003 spiro group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 229960000604 valproic acid Drugs 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 208000008811 Agoraphobia Diseases 0.000 claims 1
- 206010059245 Angiopathy Diseases 0.000 claims 1
- 206010002660 Anoxia Diseases 0.000 claims 1
- 241000976983 Anoxia Species 0.000 claims 1
- 206010003497 Asphyxia Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010006002 Bone pain Diseases 0.000 claims 1
- DKRQRHIONQXYGP-UHFFFAOYSA-N C1CCNC(C(C2=O)=O)=C2N1CCC(O)(O[PH2]=O)OC(=O)C1=CC=CC=C1 Chemical compound C1CCNC(C(C2=O)=O)=C2N1CCC(O)(O[PH2]=O)OC(=O)C1=CC=CC=C1 DKRQRHIONQXYGP-UHFFFAOYSA-N 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 206010064012 Central pain syndrome Diseases 0.000 claims 1
- 206010050217 Cervical radiculopathy Diseases 0.000 claims 1
- 208000018380 Chemical injury Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 208000021965 Glossopharyngeal Nerve disease Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000010496 Heart Arrest Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000013016 Hypoglycemia Diseases 0.000 claims 1
- 206010021030 Hypomania Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010050219 Lumbar radiculopathy Diseases 0.000 claims 1
- 208000030858 Myofascial Pain Syndromes Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010033664 Panic attack Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 206010034912 Phobia Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 206010037779 Radiculopathy Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 208000011962 Substance-induced mood disease Diseases 0.000 claims 1
- 231100000395 Substance-induced mood disorder Toxicity 0.000 claims 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 210000001015 abdomen Anatomy 0.000 claims 1
- 208000026345 acute stress disease Diseases 0.000 claims 1
- 230000007953 anoxia Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 201000005442 glossopharyngeal neuralgia Diseases 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 239000000014 opioid analgesic Substances 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 210000004197 pelvis Anatomy 0.000 claims 1
- GJVFBWCTGUSGDD-UHFFFAOYSA-L pentamethonium bromide Chemical compound [Br-].[Br-].C[N+](C)(C)CCCCC[N+](C)(C)C GJVFBWCTGUSGDD-UHFFFAOYSA-L 0.000 claims 1
- 210000002640 perineum Anatomy 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 201000001716 specific phobia Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 210000001738 temporomandibular joint Anatomy 0.000 claims 1
- 208000012720 thalamic disease Diseases 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 235000000112 undernutrition Nutrition 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
- 0 CC(*)(*)OC(N(*)*)=O Chemical compound CC(*)(*)OC(N(*)*)=O 0.000 description 2
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46149003P | 2003-04-09 | 2003-04-09 | |
| PCT/US2004/010596 WO2004092189A1 (en) | 2003-04-09 | 2004-04-07 | Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkyl phosphonic acid and their use as n-methyl-d-aspartate (nmda) recetor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006523694A JP2006523694A (ja) | 2006-10-19 |
| JP2006523694A5 true JP2006523694A5 (https=) | 2007-06-14 |
| JP4621659B2 JP4621659B2 (ja) | 2011-01-26 |
Family
ID=33299828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006509747A Expired - Fee Related JP4621659B2 (ja) | 2003-04-09 | 2004-04-07 | ［２−（８，９−ジオキソ−２，６−ジアザビシクロ［５．２．０］ノナ−１（７）−エン−２−イル）アルキル］ホスホン酸の誘導体およびｎ−メチル−ｄ−アスパルテート（ｎｍｄａ）受容体アンタゴニストとしてのその使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US7253153B2 (https=) |
| EP (1) | EP1611144B1 (https=) |
| JP (1) | JP4621659B2 (https=) |
| CN (1) | CN1863810B (https=) |
| AR (1) | AR044013A1 (https=) |
| AT (1) | ATE481103T1 (https=) |
| AU (1) | AU2004230895B2 (https=) |
| BR (1) | BRPI0409255A (https=) |
| CA (1) | CA2521313A1 (https=) |
| CL (1) | CL2004000769A1 (https=) |
| CY (1) | CY1110863T1 (https=) |
| DE (1) | DE602004029146D1 (https=) |
| DK (1) | DK1611144T3 (https=) |
| ES (1) | ES2350449T3 (https=) |
| MX (1) | MXPA05010760A (https=) |
| PL (1) | PL1611144T3 (https=) |
| PT (1) | PT1611144E (https=) |
| TW (1) | TWI349674B (https=) |
| WO (1) | WO2004092189A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7687080B2 (en) * | 2002-11-25 | 2010-03-30 | Taraxos Inc. | Treatment of neuropathy |
| US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
| GT200400213A (es) * | 2003-10-22 | 2007-09-05 | Metodos para la preparacion del acido {2-[(8,9)-dioxo-2,6-diaza-biciclo[5.2.0]-non-1(7)-en-2-il]etil} fosfonico y esteres del mismo | |
| MX2007004138A (es) * | 2004-10-08 | 2007-06-15 | Wyeth Corp | Derivados de acido [2-(8,9-dioxo-2,6-diazabiciclo [5.2.0] non-1(7)-en-2-il-) alquil] fosfonico y metodos de preparacionde los mismos. |
| EP2089383B1 (en) | 2006-11-09 | 2015-09-16 | Probiodrug AG | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
| US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| AU2008220785B2 (en) | 2007-03-01 | 2013-02-21 | Vivoryon Therapeutics N.V. | New use of glutaminyl cyclase inhibitors |
| JP5667440B2 (ja) | 2007-04-18 | 2015-02-12 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体 |
| EP2195031A1 (en) * | 2007-08-27 | 2010-06-16 | Wyeth a Corporation of the State of Delaware | Compositions and methods employing nmda antagonists for achieving an anesthetic-sparing effect |
| ES2388958T3 (es) | 2007-11-29 | 2012-10-22 | Actelion Pharmaceuticals Ltd. | Derivados de acido fosfonico y su uso como antagonista del receptor P2Y12 |
| AR071653A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-4-ciclopropil-pirimidina |
| AR071652A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2- fenil-piridina substituidos |
| EP2334176A4 (en) * | 2008-09-27 | 2012-05-02 | Taraxos Inc | TOPICAL FORMULATIONS FOR THE TREATMENT OF NERVE DISEASES |
| KR101694563B1 (ko) | 2009-04-08 | 2017-01-09 | 액테리온 파마슈티칼 리미티드 | Ａｄｐ 수용체 길항제로서 6-(3-아자-비시클로〔3.1.0〕헥스-3-일)-2-페닐-피리미딘 |
| JP5934645B2 (ja) | 2009-09-11 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体 |
| WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
| JP5688745B2 (ja) | 2010-03-10 | 2015-03-25 | プロビオドルグ エージー | グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤 |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| EP2686313B1 (en) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
| WO2012137225A1 (en) * | 2011-04-08 | 2012-10-11 | Sphaera Pharma Pvt. Ltd | Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds |
| HUE057772T2 (hu) | 2016-09-22 | 2022-06-28 | Idorsia Pharmaceuticals Ltd | Kristályos formák |
| US11179390B2 (en) | 2017-03-15 | 2021-11-23 | Idorsia Pharmaceuticals Ltd | Subcutaneous administration of a P2Y12 receptor antagonist |
| ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
| US10902020B2 (en) * | 2018-06-08 | 2021-01-26 | International Business Machines Corporation | Multiple cache processing of streaming data |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5624898A (en) * | 1989-12-05 | 1997-04-29 | Ramsey Foundation | Method for administering neurologic agents to the brain |
| US5168103A (en) * | 1991-01-22 | 1992-12-01 | American Home Products Corporation | [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives |
| US5124319A (en) * | 1991-10-11 | 1992-06-23 | American Home Products Corporation | Benzimidazole phosphono-amino acids |
| DK124393D0 (da) | 1993-11-03 | 1993-11-03 | Lundbeck & Co As H | Compounds |
| TW427904B (en) | 1995-12-07 | 2001-04-01 | American Home Prod | Neuroprotective agents |
| UA52698C2 (uk) | 1996-10-04 | 2003-01-15 | Х. Луннбек А/С | Похідні (3-алкоксіізоксазол-4-іл)заміщеної 2-амінокарбонової кислоти та їх сірковмісні аналоги, фармацевтична композиція на їх основі |
| US5990307A (en) * | 1997-08-01 | 1999-11-23 | American Home Products Corporation | Process for the preparation of [2-((8.9)-Dioxo-2,6-Diazabicyclo [5.2.0]-Non-1(7)-en-2yl) Ethyl]Phosphonic acid |
| CA2297411C (en) | 1997-08-01 | 2008-12-02 | American Home Products Corporation | Process for the preparation of [2-((8,9)- dioxo-2,6-diazabicyclo [5.2.0]-non-1(7)-en-2-yl)-ethyl] phosphonic acid |
| US6541669B1 (en) | 1998-06-08 | 2003-04-01 | Theravance, Inc. | β2-adrenergic receptor agonists |
| US6225343B1 (en) * | 1999-06-16 | 2001-05-01 | Nastech Pharmaceutical Company, Inc. | Compositions and methods comprising morphine gluconate |
| UA78529C2 (en) * | 2001-10-10 | 2007-04-10 | Wyeth Corp | Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain |
| US20040082543A1 (en) | 2002-10-29 | 2004-04-29 | Pharmacia Corporation | Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain |
| EP1622625A1 (en) * | 2003-04-09 | 2006-02-08 | Wyeth | Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo [5.2.o] non-1 (7)-en-2-yl )alkyl] phosphonic acid and derivatives and methods of use thereof |
| US6933289B2 (en) | 2003-07-01 | 2005-08-23 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
| US20050142192A1 (en) * | 2003-10-15 | 2005-06-30 | Wyeth | Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives |
-
2004
- 2004-04-07 CA CA002521313A patent/CA2521313A1/en not_active Abandoned
- 2004-04-07 EP EP04759168A patent/EP1611144B1/en not_active Expired - Lifetime
- 2004-04-07 DE DE602004029146T patent/DE602004029146D1/de not_active Expired - Lifetime
- 2004-04-07 AU AU2004230895A patent/AU2004230895B2/en not_active Ceased
- 2004-04-07 BR BRPI0409255-4A patent/BRPI0409255A/pt not_active IP Right Cessation
- 2004-04-07 ES ES04759168T patent/ES2350449T3/es not_active Expired - Lifetime
- 2004-04-07 AT AT04759168T patent/ATE481103T1/de active
- 2004-04-07 PL PL04759168T patent/PL1611144T3/pl unknown
- 2004-04-07 DK DK04759168.0T patent/DK1611144T3/da active
- 2004-04-07 US US10/820,216 patent/US7253153B2/en not_active Expired - Fee Related
- 2004-04-07 AR ARP040101199A patent/AR044013A1/es not_active Application Discontinuation
- 2004-04-07 JP JP2006509747A patent/JP4621659B2/ja not_active Expired - Fee Related
- 2004-04-07 MX MXPA05010760A patent/MXPA05010760A/es active IP Right Grant
- 2004-04-07 WO PCT/US2004/010596 patent/WO2004092189A1/en not_active Ceased
- 2004-04-07 PT PT04759168T patent/PT1611144E/pt unknown
- 2004-04-07 CN CN200480009542XA patent/CN1863810B/zh not_active Expired - Fee Related
- 2004-04-08 CL CL200400769A patent/CL2004000769A1/es unknown
- 2004-04-08 TW TW093109670A patent/TWI349674B/zh not_active IP Right Cessation
-
2007
- 2007-06-01 US US11/757,006 patent/US7879825B2/en not_active Expired - Fee Related
-
2010
- 2010-10-25 CY CY20101100967T patent/CY1110863T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006523694A5 (https=) | ||
| EP3478679B1 (en) | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases | |
| JP4621659B2 (ja) | ［２−（８，９−ジオキソ−２，６−ジアザビシクロ［５．２．０］ノナ−１（７）−エン−２−イル）アルキル］ホスホン酸の誘導体およびｎ−メチル−ｄ−アスパルテート（ｎｍｄａ）受容体アンタゴニストとしてのその使用 | |
| JP2020528062A (ja) | ピペラジンヘテロアリール誘導体、その製造方法、およびその医薬での使用 | |
| JP2006522834A5 (https=) | ||
| JP6643247B2 (ja) | ガンマセクレターゼモジュレーターとしてのクロメンおよび１，１ａ，２，７Ｂ−テトラヒドロシクロプロパ［Ｃ］クロメンピリドピラジンジオン | |
| JP6506833B2 (ja) | イミダゾピリダジン化合物 | |
| JP2009530248A5 (https=) | ||
| KR20140054068A (ko) | 테노포비어 알라펜아미드 헤미푸마레이트 | |
| JP6215971B2 (ja) | てんかん又はてんかん−関連症侯群の予防又は治療用フェニルアルキルカルバメート化合物｛ｐｈｅｎｙｌａｌｋｙｌｃａｒｂａｍａｔｅｃｏｍｐｏｕｎｄｓｆｏｒｕｓｅｉｎｐｒｅｖｅｎｔｉｎｇｏｒｔｒｅａｔｉｎｇｅｐｉｌｅｐｓｙｏｒｅｐｉｌｅｐｓｙ−ｒｅｌａｔｅｄｓｙｎｄｒｏｍｅ｝ | |
| JP2006507220A5 (https=) | ||
| JP2024536863A (ja) | イミダゾピリダジンｉｌ－１７阻害剤化合物 | |
| JP2011525185A5 (https=) | ||
| JP2019536821A (ja) | 水溶性アロプレグネノロン誘導体およびその使用 | |
| JP2020510041A5 (https=) | ||
| JP2016531880A (ja) | ガンマセクレターゼモジュレーターとしての新規二環式ピリジノン | |
| JP2020520925A (ja) | 化合物、組成物および方法 | |
| CN1503667A (zh) | 用于预防或治疗神经变性疾病的氨基甲酸酯化合物 | |
| JP2018508494A (ja) | 新規シクロプロパベンゾフラニルピリドピラジンジオン | |
| EP0644877B1 (en) | Substituted-hexahydrobenzo a phenanthridines | |
| CN1802161A (zh) | [2－(8,9－二氧代－2,6－二氮杂双环[5.2.0]壬－1(7)－烯－2－基)烷基]－膦酸及其衍生物的鼻内给药药用组合物及用法 | |
| DE602005001696D1 (de) | 4-(sulfanylpyrimidin-4-ylmethyl)morpholin-derivate und verwandte verbindungen als gaba-rezeptorliganden zur behandlung von angst, depression und epilepsie | |
| RU99103681A (ru) | Амиды альфа-аминокислот, их получение и терапевтическое применение | |
| CN1344263A (zh) | 多环的2－氨基噻唑体系、它们的制备方法和包含这些化合物的药物 | |
| CN1037342A (zh) | 膦酰烷基嘌呤衍生物 |